Verquvo
Payments companies reported to CMS as associated with Verquvo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Verquvo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Verquvo
These are the largest totals companies reported as associated with Verquvo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Javed Butler | Jackson, MS | Advanced Heart Failure and Transplant Cardiology | $233,895.26 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $213,275.33 |
| Harvey Serota | Saint Louis, MO | Interventional Cardiology | $200,455.47 |
| Warren Wexelman | Brooklyn, NY | Cardiovascular Disease | $194,745.16 |
| Georges Chahoud | Saint Louis, MO | Cardiovascular Disease | $194,091.24 |
| Prabodh Mehta | Elizabethtown, KY | Cardiovascular Disease | $173,575.96 |
| Dmitry Yaranov | Memphis, TN | Advanced Heart Failure and Transplant Cardiology | $171,121.20 |
| Robert Fowles | Salt Lake City, UT | Cardiovascular Disease | $156,944.82 |
| Naveen Bellam | Orlando, FL | Advanced Heart Failure and Transplant Cardiology | $154,998.86 |
| Robert Chilton | San Antonio, TX | Interventional Cardiology | $152,112.88 |
Prescribed Verquvo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.